购物车
- 全部删除
- 您的购物车当前为空
HJC0350 是一种有效地、选择性的EPAC2拮抗剂(IC50:0.3 µM)。
为众多的药物研发团队赋能,
让新药发现更简单!
HJC0350 是一种有效地、选择性的EPAC2拮抗剂(IC50:0.3 µM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 131 | 现货 | |
5 mg | ¥ 298 | 现货 | |
10 mg | ¥ 398 | 现货 | |
25 mg | ¥ 833 | 现货 | |
50 mg | ¥ 1,380 | 现货 | |
100 mg | ¥ 2,370 | 现货 | |
200 mg | ¥ 3,390 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 296 | 现货 |
产品描述 | HJC0350 is an effective and specific EPAC2 inhibitor (IC50: 0.3 μM), and no inhibition of Epac1. |
靶点活性 | EPAC2:0.3 μM |
体外活性 | HJC0350 专门阻断了 cAMP 引起的 EPAC2 激活,但不抑制由 cAMP 介导的 PKA 激活。在 HEK293/EPAC2-FL 细胞中,HJC0350 还能抑制 007-AM 介导的 EPAC2 的细胞激活。[1] |
激酶实验 | In Vitro IRE1 RNase and RIDD Assays: Analysis of radiolabeled Xbp1 substrate cleavage is performed as previously except that mammalian IRE1 reaction buffer is used. In vitro RIDD substrates are synthesized by in vitro transcription using the T7-MAXIscript Kit in the presence of 32P ATP or Cy5-UTP on templates isolated by RT-PCR from mouse Min6 cells (Ins2) or PCR from cloned XBP1 cDNA. The resulting products are gel purified to obtain full-length substrate. Reactions are then separated by 15% UREA-PAGE for analysis by phosphorimaging or by near-infrared imaging using the LI-COR Odyssey scanner. |
分子量 | 277.38 |
分子式 | C15H19NO2S |
CAS No. | 885434-70-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 16.67 mg/mL (60.09 mM), Sonication is recommended. Ethanol: 5.6 mg/mL (20 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.